MIM
OTLKW

Monashee Investment Management’s Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 OTLKW Stock Holding History

Monashee Investment Management’s Portfolio OTLKW Stock Details OTLKW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-25,000
Closed -$3K – 149
2019
Q3 		$3K Hold
25,000
– – ﹤0.01% 112
2019
Q2 		$3K Buy
+25,000
New +$4.67K ﹤0.01% 159

Other funds holding OTLKW

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
CIA
Compass Ion Advisors Conshohocken, Pennsylvania $1.05B AUM 16.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Monashee Investment Management's OTLKW Position: Q4 2019 in Review

Monashee Investment Management sold out of Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) in Q4 2019, closing a stake of 25,000 shares — an estimated $3K sold.

Monashee Investment Management first reported a position in OTLKW in Q2 2019 and held it in 2 quarters. The position peaked at $3K in Q3 2019. 7 funds tracked by Wall St. Rank hold OTLKW as of Q4 2019.

  • Monashee Investment Management reported no remaining Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 position as of Q4 2019 after selling out during the quarter.
  • Monashee Investment Management sold 25,000 Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 shares in Q4 2019, an estimated $3K.
  • Monashee Investment Management first reported a position in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 in Q2 2019 and held it in 2 quarters.
  • Monashee Investment Management's Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 position peaked at $3K in Q3 2019.
  • 7 funds tracked by Wall St. Rank held Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 as of Q4 2019.

Based on Monashee Investment Management's 13F filing for Q4 2019, filed 12 Feb 2020.